ATMOSPHERE: Heart Failure Trial Poisoned By Controversy (CME/CE)
(MedPage Today) -- Aliskiren raised regulatory pandemonium as it crashed in trials (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 4, 2016 Category: American Health Source Type: news
ATMOSPHERE: Heart Failure Trial Tainted By Controversy (CME/CE)
(MedPage Today) -- Aliskiren raised regulatory turmoil as trouble arose in trials (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 4, 2016 Category: American Health Source Type: news
No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
(American College of Cardiology) In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported at the American College of Cardiology's 65th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2016 Category: Global & Universal Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Nueva advertencia y contraindicación sobre medicamentos para la presión arterial que contienen aliskiren
El 20 de abril del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) advirtió sobre la probabilidad de riesgos por el uso de medicamentos para la presión arterial que contienen aliskiren combinado con otros medicamentos denominados inhibidores de la enzima convertidora de angiotensina (ACEIs por sus siglas en inglés), y los bloqueadores de los receptores de angiotensina (ARBs por sus siglas en inglés) en pacientes con diabetes o problemas renales o de riñón. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news
CardioBreak: Statins and Sex, Tekturna Black Box
(MedPage Today) -- Recent developments of interest in cardiovascular medicine. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 13, 2015 Category: Cardiology Source Type: news
Aliskiren and Antihypertensives in Elderly With HypertensionAliskiren and Antihypertensives in Elderly With Hypertension
Does BP lowering reduce cardiovascular disease in elderly individuals with SBP (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 7, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
BP, Cholesterol Drugs Recalled Over Contamination FearsBP, Cholesterol Drugs Recalled Over Contamination Fears
Novartis has sent letters to physicians informing them that free samples of Diovan, Tekturna, Lescol, and other drugs may have been contaminated by a chemical in their packaging. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2013 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Aliskiren and Outcomes in Diabetic vs Non-diabetics With HFAliskiren and Outcomes in Diabetic vs Non-diabetics With HF
Learn more about effects of a direct renin inhibitor on post-discharge outcomes in patients hospitalized for heart failure. European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Blood pressure drug tends to slow coronary disease research finds
Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research). The researchers found that the renin-inhibitor aliskiren tended to slow coronary disease progression and reduced the risk of death, stroke and heart attack in these patients by about 50 percent, compared to placebo, suggesting that patients with prehypertension may benefit from blood pressure lowering drugs... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
Medication does not slow progression of coronary disease in patients with prehypertension
Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 5, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
Blood pressure lowering drug aliskiren did not improve coronary artery disease for patients with prehypertension AQUARIUS study finds
The blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) reveal... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 5, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
ESC: No Plaque Regression With Aliskiren (CME/CE)
AMSTERDAM (MedPage Today) -- Giving the direct renin inhibitor aliskiren (Tekturna) to patients who have coronary artery disease -- but don't meet clinical criteria for hypertension -- did not slow progression of atherosclerosis, researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 3, 2013 Category: Cardiology Source Type: news
Aliskiren: No impact on atherosclerosis progression in AQUARIUS
In a new setback for the drug, the renin-inhibitor has failed to demonstrate atherosclerosis regression in patients with prehypertension. (Source: theHeart.org)
Source: theHeart.org - September 3, 2013 Category: Cardiology Source Type: news
Medication does not slow progression of coronary disease in patients with prehypertension
(The JAMA Network Journals) Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2013 Category: Global & Universal Source Type: news
Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
(European Society of Cardiology) The blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound study reveal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2013 Category: Global & Universal Source Type: news
